Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This article provides billing and coding instructions for reporting next-generation sequencing lab-developed tests used to evaluate or diagnose myeloid malignancies or suspected myeloid malignancies, and complements LCD L38125 and Related Article A58121. Claims must include the appropriate CPT and ICD-10-CM codes, one unit of service (1 UOS), and the DEX Z-Code entered adjacent to the CPT code in the specified claim fields (Loop 2400/SV101-7/Item 19 for Part B; SV202-7/Block 80 for Part A); do not add extra characters to SV101-7 entries.

"Next-generation sequencing (NGS) lab-developed test (LDT) performed to evaluate, diagnose, or characterize myeloid malignancies or suspected myeloid malignancies."

Sign up to see full coverage criteria, indications, and limitations.